SCHEMBL4482423

SCHEMBL4482423

CC(C)OCCC(C)(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7890530 0.83 ALDH1A1 (0.34)
SCHEMBL26328710 0.82
SCHEMBL10175769 0.81 ALDH1A1 (0.33)
SCHEMBL20206379 0.81 HRH3 (0.38)
SCHEMBL18609230 0.81
SCHEMBL14134716 0.79 ALDH1A1 (0.32)
SCHEMBL14134715 0.79 ALDH1A1 (0.32)
SCHEMBL22917546 0.79
SCHEMBL23706994 0.78
SCHEMBL19565595 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-07-18 US disclosed
US-20230399297-A1 Novel Glutamine Analogs JACOBIO PHARMACEUTICALS CO., LTD (CN) 2023-12-14 US disclosed
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-11-09 US disclosed
US-11807636-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-11-07 US disclosed
US-11801238-B2 Anti-viral activity of VPS34 inhibitors DECIPHERA PHARMACEUTICALS, LLC (US) 2023-10-31 US disclosed
US-11780858-B2 Pyridinamine-pyridone and pyrimidinamine-pyridone compounds SPRINT BIOSCIENCE AB (SE) 2023-10-10 US disclosed
US-20230234949-A1 MORPHOLINYLPYRIDONE COMPOUNDS SPRINT BIOSCIENCE AB (SE) 2023-07-27 US disclosed
US-20230219945-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-13 US disclosed
US-20230218638-A1 NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF SAGE THERAPEUTICS, INC. 2023-07-13 US disclosed
US-20230192756-A1 NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF Sage Therapeutics, LLC 2023-06-22 US disclosed
US-20080200446-A1 Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof SCHERING CORPORATION (US) 2008-08-21 US disclosed
US-7378518-B2 Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof SCHERING CORPORATION (US) 2008-05-27 US disclosed
US-7368562-B2 Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof SCHERING CORPORATION (US) 2008-05-06 US disclosed
US-20070155676-A1 Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof SCHERING CORPORATION (US) 2007-07-05 US disclosed
US-20070155674-A1 Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof SCHERING CORPORATION (US) 2007-07-05 US disclosed
US-7208486-B2 Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof SCHERING CORPORATION (US) 2007-04-24 US disclosed
US-7192944-B2 Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof SCHERING CORP. (US) 2007-03-20 US disclosed
US-20070043087-A1 Such as 3-{2,6-difluoro-4-[4,5-dihydro-6-(3,3-dimethylbutyl)naphtho[1,2-d]thiazol-2-ylcabamoyl)phenyl]-2-methylacrylic acid EDDINGPHARM (HONG KONG) COMPANY LIMITED (CN) 2007-02-22 US disclosed
EP-1655291-A1 COMPOUNDS HAVING THROMBOPOIETIN RECEPTOR AGONISM SHIONOGI & CO., LTD. (JP) 2006-05-10 EP disclosed
EP-0001270-A1 Analogues of prostacycline, methods for their preparation and their use in the treatment of circulatory diseases HOECHST AKTIENGESELLSCHAFT (DE) 1979-04-04 EP disclosed